A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
This study, called KarMMa-3, is for adults (18 years and older) who have multiple myeloma that has returned or not improved after at least two previous treatments, including specific types of medications. Researchers want to compare a new experimental treatment called idecabtagene vicleucel (also known as bb2121) with current standard treatments. The main goal is to see if the new treatment can keep the cancer from growing for longer. They will also look at how many people respond to treatment, how long they live, how safe the treatments are, and how they affect people's quality of life. This is a Phase 3 study, which means it's a key step to see if the new treatment should be widely available.
At a glance
What is this study about?
This clinical trial, called KarMMa-3, is focused on finding better ways to treat multiple myeloma, a type of cancer that affects plasma cells in your bone marrow. This specific study is for people whose multiple myeloma has either come back (relapsed) after previous treatments or hasn't responded well to those treatments (refractory). This can be a very challenging situation, and researchers are always looking for new and more effective options.
The main purpose of this study is to compare a new experimental treatment called idecabtagene vicleucel (also known as bb2121) with standard treatments currently used for multiple myeloma. The term 'standard regimens' refers to treatments that doctors commonly prescribe based on current medical knowledge. By comparing the new treatment to these established options, doctors can understand if the new treatment offers significant advantages in controlling the cancer.
This is a 'Phase 3' study. This means it's a large, important stage of research. Before a new medicine can be approved for general use, it needs to go through several phases. Phase 3 trials are designed to confirm how well the treatment works, understand its safety in a larger group of people, and compare it directly with existing treatments. The information gathered from studies like this helps doctors decide the best way to care for patients with multiple myeloma in the future.
Key takeaways
- This study is for adults with multiple myeloma that has come back or not responded to previous treatments.
- It compares a new experimental treatment (idecabtagene vicleucel) with existing standard treatments.
- The main goal is to see if the new treatment can keep the cancer from growing longer.
- Participation involves strict eligibility checks and close medical monitoring.
- You'll learn about potential benefits and risks, and you can withdraw at any time.
Who may be eligible?
To be considered for this study, you need to be an adult, at least 18 years old. Both men and women can take part.
Your diagnosis must be multiple myeloma that has either returned or not responded to previous treatments. Specifically, you must have tried at least two different types of treatments before. These must have included particular kinds of medicines: one called an 'immunomodulatory drug' (like lenalidomide or pomalidomide) and another called a 'proteasome inhibitor' (like bortezomib or carfilzomib).
Importantly, your cancer must have shown signs of getting worse during your last treatment, or within 60 days after you finished it. These are strict guidelines to make sure the study includes people who could benefit most from this type of research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with multiple myeloma?
- Has your multiple myeloma come back or not responded to at least two previous treatments?
- Did your cancer worsen during or within 60 days of your last treatment?
- Have your previous treatments included an 'immunomodulatory drug' AND a 'proteasome inhibitor'?
What does participation involve?
If you decide to join this study, you would be randomly assigned to receive either the new treatment (idecabtagene vicleucel) or one of the standard multiple myeloma treatments. This random assignment is like flipping a coin to ensure a fair comparison. The specific standard treatments involve different medications administered in various ways, such as injections, infusions, or capsules. You would have regular visits to the clinic for medical check-ups, blood tests, and to receive your treatment.
The research team will closely monitor your health, how your cancer responds, and any side effects you might experience. They will also collect information on your general well-being and quality of life. The study involves ongoing follow-up, and the specific duration will vary depending on your treatment and how your health progresses. Before joining, the study team will explain the full schedule of visits, tests, and treatments involved.
Potential risks and benefits
Locations (7)
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedItaly
- —UnverifiedFrance
- —UnverifiedNetherlands
- —UnverifiedBelgium
- —UnverifiedNorway
Common questions
What is idecabtagene vicleucel (bb2121)?
It's an experimental treatment being studied for multiple myeloma, aiming to target cancer cells more effectively.
What does 'relapsed and refractory' mean?
It means your multiple myeloma has either come back after treatment or hasn't responded to previous treatments.
What is a 'Phase 3' study?
It's a large study comparing a new treatment to standard treatments to see if it works better and is safe before it can be widely used.
Will I definitely get the new treatment?
You will be randomly assigned to either receive the new treatment or one of the standard treatments for multiple myeloma.
Can I leave the study if I change my mind?
Yes, you can choose to leave the study at any time, and it won't affect your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.